Ganesh Kaundinya

Ganesh Kaundinya is President and CEO of GlycoEra, a Swiss-US biotech building extracellular protein degraders to treat autoimmune disease. An MIT-trained chemical engineer, he co-founded Momenta Pharmaceuticals and helped grow it from a sugar-sequencing concept into a public company with FDA-approved products, later acquired by Johnson & Johnson for $6.5 billion. At GlycoEra he raised an oversubscribed $130 million Series B in 2025 to push a precision IgG4 degrader toward the clinic.